Labcorp Holdings Inc.

Labcorp Holdings Inc.

LH
Labcorp Holdings Inc.US flagNew York Stock Exchange
258.92
USD
+1.22
- -
21.23BMarket Cap
Labcorp Holdings Inc.
LH
(New York Stock Exchange)

Recent

price

258.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
48.87
56.67
60.66
67.77
70.89
87.86
93.2
100.66
111.77
118.03
143.66
135.84
130.23
139.63
155.05
167.69
170.77
Revenue per Share
5.45
5.31
6.24
6.7
6.03
4.43
6.94
11.98
8.71
8.41
15.99
24.58
14.04
4.8
8.89
10.53
11.37
Basic EPS, GAAP
8.62
8.75
8.97
9.55
8.71
9.94
11.68
14.61
12.87
14.76
21.95
32.16
21.47
15.24
18.9
19.72
21.9
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.14
2.92
2.9
2.89
2.9
Dividend per Share
31.82
34.75
38.5
39.49
44.77
42.87
48.47
60.63
69.94
80.82
97.51
108.22
116.24
90.65
99.06
103.94
106.15
Book Value per Share
-17.47
-18.19
-19.59
-24.32
-20.48
-46.21
-41.99
-46.31
-42.22
-44.05
-23.18
-14.49
9.54
-18.3
-21.36
-21.02
-22.29
Tangible Book Value per Share
102
98
94
86
85
99
102
102
101
98
97
97
91
87
84
83
83
Basic Weighted Avg Shares
5,004
5,542
5,671
5,808
6,012
8,680
9,553
10,308
11,333
11,555
13,978
13,136
11,864
12,162
13,009
13,952
14,144
Sales/Revenue/Turnover
19.8
18.57
18.49
17.44
15.34
12.8
13.91
13.35
12.12
11.98
21.09
23.39
14.77
9.24
8.75
10.87
11.11
Operating Margin (%)
204
231
230
230
246
458
499
533
552
577
625
577
537
577
644
681
688
Depreciation Expense
558
520
583
574
511
438
712
1,227
884
824
1,556
2,377
1,279
418
746
876
942
Net Income, GAAP
37.57
38.45
38.06
37.16
37.53
39.57
33.6
- -
30.31
25.34
29.84
23.9
18.9
33.13
22.14
20.75
18.17
Effective Tax Rate (%)
11.16
9.38
10.28
9.88
8.5
5.04
7.45
11.9
7.8
7.13
11.13
18.1
10.78
3.44
5.73
6.28
6.66
Profit Margin (%)
23
327
363
696
716
921
651
548
956
325
2,047
2,548
1,546
540
1,476
1,197
1,918
Working Capital
1,827
2,086
2,175
2,889
2,683
5,940
5,300
6,345
6,042
6,478
6,181
6,144
5,775
4,782
6,082
5,830
6,552
LT Debt
2,487
2,524
2,738
2,511
2,838
4,960
5,521
6,825
6,990
7,587
9,457
10,294
10,116
7,890
8,066
8,637
8,746
Total Equity
15.13
13.69
13.25
12.04
10.43
7.95
7.88
- -
7.14
7.39
13.18
13.99
8.54
4.95
6.03
7.82
8.36
Return on Invested Capital (%)
12.01
10.09
10.74
9.98
8.73
6.9
7.98
- -
8.06
7.11
10.87
15.33
8.45
3.58
6.16
6.84
7.23
Return on Capital (%)
18.01
15.61
16.66
16.43
14.24
10.9
15.47
21.96
13.29
10.98
17.89
23.83
12.15
4.52
9.21
10.34
10.91
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
691
696
688
LT Borrowings
5,082
5,085
5,834
LT Finance Leases
756
746
719
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
83
82
82
Market Capitalization
23,948
20,861
22,099

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4,079
4,020
4,559
Cash, Cash Equivalents & STI
598
532
981
Accounts Receivable, Net
2,109
2,104
2,289
Inventories
522
535
498
Total Current Liabilities
2,629
2,824
2,641
Payables & Accruals
1,546
1,265
1,548
ST Debt
691
696
688
Deferred Revenue
392
439
405

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.5%
-1.12%
7.07%
Free Cash Flow
9.18%
-0.14%
3.45%
Net Income, GAAP
22.44%
7.04%
17.49%
Sales/Revenue/Turnover
5.19%
0.2%
7.25%
Total Cash Common Dividend
- -
- -
-0.99%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,177
3,221
3,282
3,329
13,009
2025
3,345
3,527
3,564
3,516
13,952
2026
3,538
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.71
2.44
2.02
1.72
8.89
2025
2.55
2.85
3.14
2
10.53
2026
3.38
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.74
0.72
0.72
0.72
2.9
2025
0.74
0.72
0.72
0.72
2.89
2026
0.74
- -
- -
- -
- -
Business
Labcorp Holdings Inc. (NYSE: LH), headquartered in Burlington, North Carolina, and founded in 1971, operates as a global life sciences and healthcare company that provides comprehensive laboratory diagnostics and biopharma drug development services across more than 100 countries, with primary operations in the United States; the company conducts business through two main segments, Diagnostics Laboratories and Biopharma Laboratory Services. The Diagnostics Laboratories segment offers routine clinical testing and specialty/esoteric testing, including over 5,000 tests in areas such as oncology, genetics and genomics, women's health, autoimmune diseases, neurology, HIV genotyping and phenotyping, employment screening, DNA parentage and immigration testing, environmental monitoring, wellness, toxicology, pain management, and medical drug monitoring, delivered via approximately 2,000 patient service centers, more than 6,000 in-office phlebotomists, rapid response laboratories, primary laboratories, specialty laboratories, and 50 at-home tests, processing over 700 million tests annually for patients, physicians, hospitals, health systems, managed care organizations, employers, governments, and consumers. The Biopharma Laboratory Services segment delivers end-to-end drug development, medical device, and diagnostic development support to pharmaceutical, biotechnology, medical device, crop protection, and chemical companies, encompassing early development research, central laboratory services, clinical trial testing, and companion diagnostics, supporting more than 75% of new FDA-approved drugs and therapeutics in 2024. In recent developments, Labcorp completed the acquisition of select oncology and clinical testing assets from BioReference Health in September 2025 for up to $225 million to bolster its oncology leadership; acquired assets of Invitae in August 2024 for $239 million to expand genetic testing capabilities; signed agreements to acquire select assets of Empire City Laboratories and Laboratory Alliance of Central New York in 2025 while progressing the Community Health Systems outreach business acquisition across 13 states; launched new Alzheimer's neurology tests, Labcorp Test Finder tool, and consumer tests via Labcorp OnDemand; invested $268.4 million in acquisitions and partnerships during Q3 2025; and expanded its credit facility to $700 million in January 2025.

Company News

APIChat
  • Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

  • Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

  • Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

  • Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

  • LH or MEDP: Which Is the Better Value Stock Right Now?

  • Labcorp to Present at the Jefferies Global Healthcare Conference

  • Labcorp (LH) Upgraded to Buy: Here's What You Should Know

  • Should You Continue to Hold Labcorp Stock in Your Portfolio?

  • Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term

  • Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time

  • Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

  • LH vs. CRL: Which Stock Is the Better Value Option?

  • Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now

  • LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

  • Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

  • Labcorp Advances As AI Investments, Core Businesses Drive Growth

  • Here's Why Labcorp Holdings (LH) is a Strong Value Stock

  • Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

  • Labcorp Holdings (LH) Q1 Earnings and Revenues Top Estimates